Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
1. Rein Therapeutics has received UK MHRA approval for Phase 2 trial of LTI-03. 2. LTI-03 targets idiopathic pulmonary fibrosis, a severe lung disease. 3. Trial will enroll 120 patients, assessing safety and lung function. 4. Initial data from the trial is expected in 2026. 5. LTI-03's success could transform pulmonary fibrosis treatment and shareholder value.